高雄醫師會誌94期-病例討論~張盛皇、王照元-癌思停(Bevacizumab)治療轉移性結直腸癌導致之偽動脈瘤破裂
•
0 likes•171 views
This document discusses the case of a 65-year-old patient (stage IVB colorectal cancer) who received chemotherapy with FOLFIRI plus Bevacizumab starting in May 2016. It provides details on the patient's treatment and discusses studies showing that combining Bevacizumab with chemotherapy improves outcomes for metastatic colorectal cancer patients compared to chemotherapy alone. Safety data from clinical trials and a meta-analysis found the Bevacizumab combination to be well-tolerated.
Report
Share
Report
Share
Download to read offline
Recommended
Adjuvant Therapy and Clinical Trials
Presented by Sapna Patel, MD. Presented at the 2018 Eyes on a Cure: Patient & Caregiver Symposium, hosted by the Melanoma Research Foundation's CURE OM initiative.
ACHO 2017 - Rectal cancer
1) Treatment of rectal cancer involves a multimodal approach combining chemotherapy, radiation therapy, and surgery depending on the stage of disease.
2) For locally advanced stages, preoperative chemoradiation is preferred to improve local control and rates of sphincter preservation compared to postoperative chemoradiation.
3) Short course preoperative radiation is non-inferior to long course chemoradiation in terms of local recurrence rates according to a randomized trial, though the optimal approach remains unclear.
T1g3
1) Treatment options for high-grade T1 bladder cancer include transurethral resection of the bladder tumor, followed by instillation of bacillus Calmette-Guérin or chemotherapy agents. Radical cystectomy or deferred radical cystectomy are also options.
2) Pathology assessment after resection provides important information on grade, depth of invasion, lymphovascular invasion, and presence of carcinoma in situ which impact risk stratification and adjuvant treatment decisions.
3) Risk of recurrence and progression is stratified using EORTC risk tables though they do not include important factors like substaging, lymphovascular invasion, and gender. Radical cystectomy is recommended for BCG-refractory, resistant
ACHO 2017 - Anal Cancer - Version 3
Presentada en el marco del Primer Simposiso de Cáncer Gastrointestinal - ACHO. Hotel Sonesta, Bogotá, 29.07.2017.
Se corrigen slides 3, 11 y 16; se adiciona slide de metastásico, que se ubica antes de la sección de antiangiogénicos.
Tracing the Arc of Immunotherapy in Melanoma: Insights on the Current Role an...
Tracing the Arc of Immunotherapy in Melanoma: Insights on the Current Role an...PVI, PeerView Institute for Medical Education
This document provides a summary of immune checkpoint inhibitors used in melanoma care, including ipilimumab, nivolumab, and pembrolizumab. It lists the FDA-approved indications for each as first-line or adjuvant therapy for unresectable or metastatic melanoma. The dosing schedules are also provided. Additionally, it outlines how to manage immune-mediated adverse reactions to checkpoint inhibitors, noting the most common types and treatment approach based on severity grade.Adjuvant therapy - Dr. Roda Amaria
Dr. Roda Amaria presents the latest on adjuvant therapy for melanoma at the MRF's Patient Symposium at MD Anderson Cancer Center on January 31, 2015.
Bladder cancer Dr abeer Elsayed
Bladder cancer is a common malignancy with risk factors including smoking, chemicals, and parasites. Most cases are transitional cell carcinoma. Superficial cancers are staged Ta-T1 while muscle-invasive are T2-T4. Treatment depends on stage and risk of recurrence. For superficial disease, transurethral resection and intravesical therapies like BCG are used. Muscle-invasive cancers require radical cystectomy with lymph node dissection and urinary diversion. Neoadjuvant chemotherapy may allow organ preservation in some. Close follow up monitors for recurrence or progression.
WTAP
This document discusses a study investigating the association between expression of the WTAP protein and glioma patient prognosis. The study aims to determine if WTAP expression levels in glioma patients correlates with survival outcomes. The methodology section describes using western blot and immunohistochemical assays to analyze WTAP protein levels in glioma patient samples. The results section finds that increased WTAP expression is associated with decreased patient survival time, suggesting WTAP may serve as a new prognostic marker. WTAP expression levels were also found to correlate with glioma grade, with higher grades exhibiting greater WTAP overexpression. The conclusion is that WTAP expression, age, glioma grade, and performance status are associated with glioma patient survival.
Recommended
Adjuvant Therapy and Clinical Trials
Presented by Sapna Patel, MD. Presented at the 2018 Eyes on a Cure: Patient & Caregiver Symposium, hosted by the Melanoma Research Foundation's CURE OM initiative.
ACHO 2017 - Rectal cancer
1) Treatment of rectal cancer involves a multimodal approach combining chemotherapy, radiation therapy, and surgery depending on the stage of disease.
2) For locally advanced stages, preoperative chemoradiation is preferred to improve local control and rates of sphincter preservation compared to postoperative chemoradiation.
3) Short course preoperative radiation is non-inferior to long course chemoradiation in terms of local recurrence rates according to a randomized trial, though the optimal approach remains unclear.
T1g3
1) Treatment options for high-grade T1 bladder cancer include transurethral resection of the bladder tumor, followed by instillation of bacillus Calmette-Guérin or chemotherapy agents. Radical cystectomy or deferred radical cystectomy are also options.
2) Pathology assessment after resection provides important information on grade, depth of invasion, lymphovascular invasion, and presence of carcinoma in situ which impact risk stratification and adjuvant treatment decisions.
3) Risk of recurrence and progression is stratified using EORTC risk tables though they do not include important factors like substaging, lymphovascular invasion, and gender. Radical cystectomy is recommended for BCG-refractory, resistant
ACHO 2017 - Anal Cancer - Version 3
Presentada en el marco del Primer Simposiso de Cáncer Gastrointestinal - ACHO. Hotel Sonesta, Bogotá, 29.07.2017.
Se corrigen slides 3, 11 y 16; se adiciona slide de metastásico, que se ubica antes de la sección de antiangiogénicos.
Tracing the Arc of Immunotherapy in Melanoma: Insights on the Current Role an...
Tracing the Arc of Immunotherapy in Melanoma: Insights on the Current Role an...PVI, PeerView Institute for Medical Education
This document provides a summary of immune checkpoint inhibitors used in melanoma care, including ipilimumab, nivolumab, and pembrolizumab. It lists the FDA-approved indications for each as first-line or adjuvant therapy for unresectable or metastatic melanoma. The dosing schedules are also provided. Additionally, it outlines how to manage immune-mediated adverse reactions to checkpoint inhibitors, noting the most common types and treatment approach based on severity grade.Adjuvant therapy - Dr. Roda Amaria
Dr. Roda Amaria presents the latest on adjuvant therapy for melanoma at the MRF's Patient Symposium at MD Anderson Cancer Center on January 31, 2015.
Bladder cancer Dr abeer Elsayed
Bladder cancer is a common malignancy with risk factors including smoking, chemicals, and parasites. Most cases are transitional cell carcinoma. Superficial cancers are staged Ta-T1 while muscle-invasive are T2-T4. Treatment depends on stage and risk of recurrence. For superficial disease, transurethral resection and intravesical therapies like BCG are used. Muscle-invasive cancers require radical cystectomy with lymph node dissection and urinary diversion. Neoadjuvant chemotherapy may allow organ preservation in some. Close follow up monitors for recurrence or progression.
WTAP
This document discusses a study investigating the association between expression of the WTAP protein and glioma patient prognosis. The study aims to determine if WTAP expression levels in glioma patients correlates with survival outcomes. The methodology section describes using western blot and immunohistochemical assays to analyze WTAP protein levels in glioma patient samples. The results section finds that increased WTAP expression is associated with decreased patient survival time, suggesting WTAP may serve as a new prognostic marker. WTAP expression levels were also found to correlate with glioma grade, with higher grades exhibiting greater WTAP overexpression. The conclusion is that WTAP expression, age, glioma grade, and performance status are associated with glioma patient survival.
Desmoid final
1) Aggressive fibromatosis is a rare soft tissue tumor that typically affects young adults. Surgery is the main treatment but recurrence is common.
2) New evidence shows systemic therapies like sorafenib, hormonal therapies, and chemotherapy can control the disease. A large trial found sorafenib significantly reduced recurrence compared to placebo.
3) Further research is still needed to determine optimal chemotherapy regimens and biomarkers to predict response to various treatments. "Wait and watch" may be suitable for less aggressive cases. Management of fibromatosis remains challenging due to the lack of high-quality data from India and validated patient-reported outcome measures.
Molecular imaging
The lecture documents the basic utility of molecular imaging tools in radiology and nuclear medicine i.e. PET-CT
Tratamiento de cáncer de colon metastásico: de las guías de práctica, genómic...
1) The document discusses treatment guidelines and clinical trials for metastatic colorectal cancer. It summarizes several studies evaluating different chemotherapy regimens and targeted therapies as first-line and second-line treatment options.
2) Location of the primary tumor is noted as an important factor in prognosis. Studies presented at ASCO 2016 evaluated the relationship between tumor location and outcomes with various treatments.
3) Ongoing research is exploring continuing anti-angiogenic therapies beyond progression and evaluating new combination regimens incorporating agents like ziv-aflibercept.
Updates on management of metastatic melanoma
This document presents a case study on metastatic melanoma. It outlines the investigations performed which included a full-thickness biopsy with margins, pathology report including Breslow thickness and ulceration status, sentinel lymph node biopsy using blue dye and radiocolloid, and imaging for staging. Management options discussed include surgery, immunotherapy like CTLA-4 and PD-1 inhibitors, targeted therapy for BRAF/KIT mutations, and clinical trials. Clinical trials showed improved overall survival with combinations of nivolumab and ipilimumab compared to monotherapies.
Gamma knife in posterior third ventricular tumors
1) The study evaluated the effectiveness of gamma knife (GK) surgery as primary or adjuvant treatment for posterior third ventricular tumors in 17 patients over 12 years.
2) Tumor control was achieved in 13 of 14 patients (92.8%) with an average follow up of 31 months, with 7 patients showing tumor reduction and 6 showing no change.
3) Primary GK achieved 100% tumor control for benign diseases and showed good control of malignant pinealoblastomas and metastases for up to 27 months.
Neoadjuvant or adjuvant immunotherapy in melanoma stage iii
The advent of neoadjuvant therapy in malignant melanoma might prove to be practice changing. Though still in research yet OPACIN and Neo OPACIN trials have unraveled the potential of neoadjuvant immunotherapy in malignant melanoma
bevacizumab hcp interview pre-work_completed
This document provides information for a pre-interview assessment, including two questions about the average number of new and existing patients treated monthly with various cancers and therapies involving bevacizumab. For question 1, the average new patients per month range from 1-15 depending on the cancer and regimen. For question 2, the average existing patients treated monthly range from 1-54 depending on the cancer and regimen. The document lists 13 cancer types and regimens involving bevacizumab to answer the two questions.
Should triple negative breast cancer (tnbc) subtype
Triple-negative breast cancer (TNBC) is an aggressive subtype without targets for hormonal or HER2-directed therapy. While historically considered poor candidates for breast-conserving surgery, several studies have shown comparable or better outcomes for selected TNBC patients treated with lumpectomy and radiation compared to mastectomy. Genetic testing is recommended for TNBC patients to guide risk-reducing interventions, though mutation status alone should not determine local-regional management. Definitive local therapy combined with conventional radiation remains the standard of care for TNBC. Ongoing research aims to identify new targets for this challenging breast cancer subtype.
Presentation study protocol
The document outlines the rationale and protocol for a study investigating micrometastases in pN0 colon cancer patients. It notes high recurrence rates in this group and aims to 1) improve risk stratification and 2) study the impact of adjuvant chemotherapy for pN0micro+ patients. The proposed study is a multicenter, randomized clinical trial that will examine lymph nodes from pN0 colon cancer patients using serial sectioning and immunohistochemistry to detect micrometastases, and randomize pN0micro+ patients to observation or adjuvant chemotherapy to evaluate 3-year disease-free survival.
Gist
Gastrointestinal stromal tumors (GISTs) are rare mesenchymal tumors that arise in the gastrointestinal tract. They range in size from a few millimeters to over 30 cm. Microscopically, GISTs contain eosinophilic structures that stain brightly with PAS. Symptoms are non-specific and include abdominal pain, bleeding, and early satiety. Diagnostic evaluations include CT, EUS, and biopsy. Treatment depends on tumor size and risk of recurrence or metastasis. For resectable disease, surgery is typically recommended, while imatinib is recommended for unresectable, metastatic, or recurrent tumors. Long-term surveillance is important due to the risk of recurrence within the first
Cancer gastrico adyuvancia
The document discusses adjuvant treatment options for gastric cancer based on several clinical trials. It finds that adjuvant chemotherapy provides a 5.8% absolute benefit in 5-year overall survival compared to surgery alone. Adjuvant chemoradiotherapy may provide additional benefits for patients with D1 resections, lymph node ratios over 25%, or intestinal-type gastric cancers. Specifically, one trial found 5-year disease-free survival was 55% with chemoradiotherapy versus 28% with chemotherapy alone for these high-risk patients. The document concludes that adjuvant chemoradiotherapy should be considered for these poor prognosis patients when neoadjuvant treatment is not possible due to poor performance status.
MBM - Melanoma Brain Metastases
Ponencia para el preceptorship LatCan en el Conrad Hotel, Miami, 14.09.2018 - Auspiciado por Novartis
Immunotherapy for Uveal Melanoma - Udai Kammula, MD, FACS
Udai Kammula, MD, FACS presents Immunotherapy for Uveal Melanoma at the 2017 CURE OM Patient & Caregiver Symposium.
Pre and postmastectomy care philippine society of oncology by roel tolentino
Pre and postmastectomy care philippine society of oncology by roel tolentinoProf. Roel Tolentino, MD, MBA
The document discusses pre and postmastectomy care. It provides information on diagnosing breast cancer through mammography and biopsies. It then covers surgical treatments for breast cancer like mastectomy, lumpectomy, and breast reconstruction procedures. Post-surgical care involves pain management, wound healing, drain care and potential complications. The document also discusses cancer staging, chemotherapy, radiation therapy, recurrence, metastasis and palliative care. The overall goal discussed is improving patient outcomes through education and proper care.ONCOLOGY - Gefitinib or Placebo in Combination with Tamoxifen in Patients wit...
Increased growth factor signaling may contribute to tamoxifen resistance. This randomized phase II trial assessed tamoxifen plus placebo or the epidermal growth factor receptor inhibitor gefitinib in estrogen receptor (ER)–positive metastatic breast cancer.
Melanoma Conference 2015
Melanoma 2015: 25th Annual Cutaneous Malignancy Update
January 10-11, 2015
Hyatt Regency Mission Bay, San Diego, California
Adyuvancia melanoma BRAF mutado
1) The document describes a clinical trial evaluating adjuvant dabrafenib plus trametinib for resected stage III BRAF V600-mutant melanoma.
2) Eligible patients underwent complete resection of stage IIIA-C melanoma and were randomized 1:1 to dabrafenib plus trametinib or placebo for up to 1 year.
3) Updated results with a median follow-up of 44 months showed significantly longer relapse-free survival for the dabrafenib/trametinib arm compared to placebo, with 59% vs 40% of patients relapse-free at 3 years.
Metastatic soft tissue sarcoma options
This document discusses several dilemmas in treating soft tissue sarcomas including whether repeat histopathology is needed at recurrence, options for first line chemotherapy including ifosfamide/doxorubicin vs doxorubicin alone vs olaratumab plus doxorubicin. It also discusses considerations for first line treatment in elderly populations and non-anthracycline regimens. Other topics covered include toxicities of pazopanib seen in Indian patients, use of trabectidin beyond its FDA approved indication, analysis of the eribulin approval, and role of histology-directed and immunotherapy approaches. Multidisciplinary care is emphasized as mandatory for optimal sarcoma management.
Adjuvant and Neoadjuvant Therapy in Melanoma - Rodabe N. Amaria, MD
This document discusses adjuvant and neoadjuvant therapy options for melanoma. Adjuvant therapy is given after surgery to lower the risk of recurrence, while neoadjuvant therapy is given before surgery. FDA-approved adjuvant therapies include interferon-alpha, pegylated interferon, and high-dose ipilimumab. Ongoing clinical trials are testing newer agents like BRAF/MEK inhibitors and anti-PD-1 antibodies in the adjuvant setting. Neoadjuvant therapy may help shrink tumors before surgery. Clinical trials are exploring neoadjuvant targeted therapies and immunotherapies and have shown potential for improved outcomes over standard surgery alone.
Concurrent Chemoradiation in Postoperative Setting In LAHNC. A comparision of...
A journal club presentation comparing and contrasting the EORTC and RTOG trials of concurrent chemoradiation in Head Neck Cancers in the post operative setting.
高雄醫師會誌94期-醫學專欄~莊來復-肝功能檢驗及判讀
1. Various clinical signs and symptoms are associated with liver disease including jaundice, spider naevi, palmar erythema, and ascites. The Child-Pugh score is used to assess prognosis in cirrhosis patients.
2. Liver enzymes AST and ALT are elevated in liver disease but the pattern of elevation can indicate different conditions - AST>ALT suggests cirrhosis while ALT>AST suggests chronic active hepatitis or alcoholic hepatitis.
3. Liver biopsy can be used to diagnose liver disease but also examines AST and ALT levels as well as calculating the AST/ALT ratio which again can point to different diseases.
More Related Content
What's hot
Desmoid final
1) Aggressive fibromatosis is a rare soft tissue tumor that typically affects young adults. Surgery is the main treatment but recurrence is common.
2) New evidence shows systemic therapies like sorafenib, hormonal therapies, and chemotherapy can control the disease. A large trial found sorafenib significantly reduced recurrence compared to placebo.
3) Further research is still needed to determine optimal chemotherapy regimens and biomarkers to predict response to various treatments. "Wait and watch" may be suitable for less aggressive cases. Management of fibromatosis remains challenging due to the lack of high-quality data from India and validated patient-reported outcome measures.
Molecular imaging
The lecture documents the basic utility of molecular imaging tools in radiology and nuclear medicine i.e. PET-CT
Tratamiento de cáncer de colon metastásico: de las guías de práctica, genómic...
1) The document discusses treatment guidelines and clinical trials for metastatic colorectal cancer. It summarizes several studies evaluating different chemotherapy regimens and targeted therapies as first-line and second-line treatment options.
2) Location of the primary tumor is noted as an important factor in prognosis. Studies presented at ASCO 2016 evaluated the relationship between tumor location and outcomes with various treatments.
3) Ongoing research is exploring continuing anti-angiogenic therapies beyond progression and evaluating new combination regimens incorporating agents like ziv-aflibercept.
Updates on management of metastatic melanoma
This document presents a case study on metastatic melanoma. It outlines the investigations performed which included a full-thickness biopsy with margins, pathology report including Breslow thickness and ulceration status, sentinel lymph node biopsy using blue dye and radiocolloid, and imaging for staging. Management options discussed include surgery, immunotherapy like CTLA-4 and PD-1 inhibitors, targeted therapy for BRAF/KIT mutations, and clinical trials. Clinical trials showed improved overall survival with combinations of nivolumab and ipilimumab compared to monotherapies.
Gamma knife in posterior third ventricular tumors
1) The study evaluated the effectiveness of gamma knife (GK) surgery as primary or adjuvant treatment for posterior third ventricular tumors in 17 patients over 12 years.
2) Tumor control was achieved in 13 of 14 patients (92.8%) with an average follow up of 31 months, with 7 patients showing tumor reduction and 6 showing no change.
3) Primary GK achieved 100% tumor control for benign diseases and showed good control of malignant pinealoblastomas and metastases for up to 27 months.
Neoadjuvant or adjuvant immunotherapy in melanoma stage iii
The advent of neoadjuvant therapy in malignant melanoma might prove to be practice changing. Though still in research yet OPACIN and Neo OPACIN trials have unraveled the potential of neoadjuvant immunotherapy in malignant melanoma
bevacizumab hcp interview pre-work_completed
This document provides information for a pre-interview assessment, including two questions about the average number of new and existing patients treated monthly with various cancers and therapies involving bevacizumab. For question 1, the average new patients per month range from 1-15 depending on the cancer and regimen. For question 2, the average existing patients treated monthly range from 1-54 depending on the cancer and regimen. The document lists 13 cancer types and regimens involving bevacizumab to answer the two questions.
Should triple negative breast cancer (tnbc) subtype
Triple-negative breast cancer (TNBC) is an aggressive subtype without targets for hormonal or HER2-directed therapy. While historically considered poor candidates for breast-conserving surgery, several studies have shown comparable or better outcomes for selected TNBC patients treated with lumpectomy and radiation compared to mastectomy. Genetic testing is recommended for TNBC patients to guide risk-reducing interventions, though mutation status alone should not determine local-regional management. Definitive local therapy combined with conventional radiation remains the standard of care for TNBC. Ongoing research aims to identify new targets for this challenging breast cancer subtype.
Presentation study protocol
The document outlines the rationale and protocol for a study investigating micrometastases in pN0 colon cancer patients. It notes high recurrence rates in this group and aims to 1) improve risk stratification and 2) study the impact of adjuvant chemotherapy for pN0micro+ patients. The proposed study is a multicenter, randomized clinical trial that will examine lymph nodes from pN0 colon cancer patients using serial sectioning and immunohistochemistry to detect micrometastases, and randomize pN0micro+ patients to observation or adjuvant chemotherapy to evaluate 3-year disease-free survival.
Gist
Gastrointestinal stromal tumors (GISTs) are rare mesenchymal tumors that arise in the gastrointestinal tract. They range in size from a few millimeters to over 30 cm. Microscopically, GISTs contain eosinophilic structures that stain brightly with PAS. Symptoms are non-specific and include abdominal pain, bleeding, and early satiety. Diagnostic evaluations include CT, EUS, and biopsy. Treatment depends on tumor size and risk of recurrence or metastasis. For resectable disease, surgery is typically recommended, while imatinib is recommended for unresectable, metastatic, or recurrent tumors. Long-term surveillance is important due to the risk of recurrence within the first
Cancer gastrico adyuvancia
The document discusses adjuvant treatment options for gastric cancer based on several clinical trials. It finds that adjuvant chemotherapy provides a 5.8% absolute benefit in 5-year overall survival compared to surgery alone. Adjuvant chemoradiotherapy may provide additional benefits for patients with D1 resections, lymph node ratios over 25%, or intestinal-type gastric cancers. Specifically, one trial found 5-year disease-free survival was 55% with chemoradiotherapy versus 28% with chemotherapy alone for these high-risk patients. The document concludes that adjuvant chemoradiotherapy should be considered for these poor prognosis patients when neoadjuvant treatment is not possible due to poor performance status.
MBM - Melanoma Brain Metastases
Ponencia para el preceptorship LatCan en el Conrad Hotel, Miami, 14.09.2018 - Auspiciado por Novartis
Immunotherapy for Uveal Melanoma - Udai Kammula, MD, FACS
Udai Kammula, MD, FACS presents Immunotherapy for Uveal Melanoma at the 2017 CURE OM Patient & Caregiver Symposium.
Pre and postmastectomy care philippine society of oncology by roel tolentino
Pre and postmastectomy care philippine society of oncology by roel tolentinoProf. Roel Tolentino, MD, MBA
The document discusses pre and postmastectomy care. It provides information on diagnosing breast cancer through mammography and biopsies. It then covers surgical treatments for breast cancer like mastectomy, lumpectomy, and breast reconstruction procedures. Post-surgical care involves pain management, wound healing, drain care and potential complications. The document also discusses cancer staging, chemotherapy, radiation therapy, recurrence, metastasis and palliative care. The overall goal discussed is improving patient outcomes through education and proper care.ONCOLOGY - Gefitinib or Placebo in Combination with Tamoxifen in Patients wit...
Increased growth factor signaling may contribute to tamoxifen resistance. This randomized phase II trial assessed tamoxifen plus placebo or the epidermal growth factor receptor inhibitor gefitinib in estrogen receptor (ER)–positive metastatic breast cancer.
Melanoma Conference 2015
Melanoma 2015: 25th Annual Cutaneous Malignancy Update
January 10-11, 2015
Hyatt Regency Mission Bay, San Diego, California
Adyuvancia melanoma BRAF mutado
1) The document describes a clinical trial evaluating adjuvant dabrafenib plus trametinib for resected stage III BRAF V600-mutant melanoma.
2) Eligible patients underwent complete resection of stage IIIA-C melanoma and were randomized 1:1 to dabrafenib plus trametinib or placebo for up to 1 year.
3) Updated results with a median follow-up of 44 months showed significantly longer relapse-free survival for the dabrafenib/trametinib arm compared to placebo, with 59% vs 40% of patients relapse-free at 3 years.
Metastatic soft tissue sarcoma options
This document discusses several dilemmas in treating soft tissue sarcomas including whether repeat histopathology is needed at recurrence, options for first line chemotherapy including ifosfamide/doxorubicin vs doxorubicin alone vs olaratumab plus doxorubicin. It also discusses considerations for first line treatment in elderly populations and non-anthracycline regimens. Other topics covered include toxicities of pazopanib seen in Indian patients, use of trabectidin beyond its FDA approved indication, analysis of the eribulin approval, and role of histology-directed and immunotherapy approaches. Multidisciplinary care is emphasized as mandatory for optimal sarcoma management.
Adjuvant and Neoadjuvant Therapy in Melanoma - Rodabe N. Amaria, MD
This document discusses adjuvant and neoadjuvant therapy options for melanoma. Adjuvant therapy is given after surgery to lower the risk of recurrence, while neoadjuvant therapy is given before surgery. FDA-approved adjuvant therapies include interferon-alpha, pegylated interferon, and high-dose ipilimumab. Ongoing clinical trials are testing newer agents like BRAF/MEK inhibitors and anti-PD-1 antibodies in the adjuvant setting. Neoadjuvant therapy may help shrink tumors before surgery. Clinical trials are exploring neoadjuvant targeted therapies and immunotherapies and have shown potential for improved outcomes over standard surgery alone.
Concurrent Chemoradiation in Postoperative Setting In LAHNC. A comparision of...
A journal club presentation comparing and contrasting the EORTC and RTOG trials of concurrent chemoradiation in Head Neck Cancers in the post operative setting.
What's hot (20)
Tratamiento de cáncer de colon metastásico: de las guías de práctica, genómic...
Tratamiento de cáncer de colon metastásico: de las guías de práctica, genómic...
Neoadjuvant or adjuvant immunotherapy in melanoma stage iii
Neoadjuvant or adjuvant immunotherapy in melanoma stage iii
Should triple negative breast cancer (tnbc) subtype
Should triple negative breast cancer (tnbc) subtype
Immunotherapy for Uveal Melanoma - Udai Kammula, MD, FACS
Immunotherapy for Uveal Melanoma - Udai Kammula, MD, FACS
Pre and postmastectomy care philippine society of oncology by roel tolentino
Pre and postmastectomy care philippine society of oncology by roel tolentino
ONCOLOGY - Gefitinib or Placebo in Combination with Tamoxifen in Patients wit...
ONCOLOGY - Gefitinib or Placebo in Combination with Tamoxifen in Patients wit...
Adjuvant and Neoadjuvant Therapy in Melanoma - Rodabe N. Amaria, MD
Adjuvant and Neoadjuvant Therapy in Melanoma - Rodabe N. Amaria, MD
Concurrent Chemoradiation in Postoperative Setting In LAHNC. A comparision of...
Concurrent Chemoradiation in Postoperative Setting In LAHNC. A comparision of...
Viewers also liked
高雄醫師會誌94期-醫學專欄~莊來復-肝功能檢驗及判讀
1. Various clinical signs and symptoms are associated with liver disease including jaundice, spider naevi, palmar erythema, and ascites. The Child-Pugh score is used to assess prognosis in cirrhosis patients.
2. Liver enzymes AST and ALT are elevated in liver disease but the pattern of elevation can indicate different conditions - AST>ALT suggests cirrhosis while ALT>AST suggests chronic active hepatitis or alcoholic hepatitis.
3. Liver biopsy can be used to diagnose liver disease but also examines AST and ALT levels as well as calculating the AST/ALT ratio which again can point to different diseases.
Trabajo de investigacion - tanatologia
Este documento trata sobre la tanatología, que es el estudio científico de la muerte. Explica conceptos clave como los tipos de muerte, fenómenos cadavéricos, tanatocronodiagnóstico y autopsia. Resume que la tanatología estudia el proceso de muerte desde perspectivas psicológica, social, profesional y técnica. Describe los cambios que sufre el cuerpo luego de la muerte como enfriamiento, deshidratación y lividez cadavérica, así como procesos posteriores
Belinda Waller and Andrew Williams' presentation at Mumbrella's Retail Market...
Jeanswest's Belinda Waller and Pencil&Pixel's Andrew Williams present on How Iconic Aussie Retailers are Fighting The Fast-Fashion Frenzy at Mumbrella's Retail Marketing Summit.
Tureesiin hariltsaa praktic
Түрээсийн гэрээ нь хуульд заасан хэлбэрийн шаардлага хангасан эсэх, улмаар хүчин төгөлдөр эсэх талаархи маргааны талаар судалсан шүүхийн практикийн танилцуулгыг ЭНД дарж үзнэ үү.
IT_CV
Benzily Joy George is a banking and IT professional with over 11 years of experience in fields including banking operations, IT sales, hardware, networking, software development and database administration. They are seeking a challenging job utilizing their skills in a heterogeneous IT environment to contribute to organizational growth. Their experience includes roles in credit analysis, business consulting, IT, networking and software development.
Banking & IT Professional Resume
Benzily Joy George is a banking and IT professional with over 11 years of experience in fields including credit operations, IT sales, hardware, networking, software development and database administration. They are seeking a challenging job utilizing their skills in a heterogeneous IT environment to contribute to organizational growth. Their experience includes roles in credit analysis, business consulting, IT, networking and sales.
Internacionalização do Negócio de Software
O documento fornece um guia estratégico para internacionalização de negócios de software, discutindo benefícios e custos, fatores a serem considerados e um roadmap sugerido. Ele destaca a importância de (1) planejamento estratégico para reduzir riscos e custos, (2) adequação de produtos, processos e cultura à atuação internacional, e (3) foco contínuo nas necessidades versus oportunidades dos mercados-alvo.
Glosario de términos
El documento presenta definiciones de varios términos clave relacionados con negocios y economía. Algunos de los términos definidos son activos, administración, autonomía, beneficios, bienes, capital, comercio, corporación, crédito, economía, empresa, estrategia, factibilidad, finanzas, inversión, mediana empresa, mercado, microempresa, pequeña empresa y plan de negocios.
高雄醫師會誌94期-會員園地~沈茂昌-吉爾吉斯尋幽探勝
Almaty is the largest city in Kazakhstan, with a population of over 1.7 million. Some key facts about Almaty include that it was founded in 1854, served as the capital until 1997, and is home to many historical and cultural sites such as the Zenkov Cathedral and Medeo skating rink. Almaty has experienced several earthquakes over the years, including a 2011 quake that caused damage, and is located near the Trans-Ili Alatau mountains.
Maria jose carrasquero
Este documento resume los conceptos clave de la medicina legal relacionados con la muerte y el estudio de cadáveres. Explica cómo se determina la data de la muerte a través del enfriamiento cadavérico, la detención de la circulación sanguínea, y la rigidez muscular. También describe los diferentes tipos de muerte, los fenómenos cadavéricos que ocurren con el tiempo, y los factores que influyen en la descomposición. Finalmente, resume los procedimientos legales para el levantamiento, inhumación, cremación y exam
Producción material-y-simbólica
El documento describe la producción material y simbólica durante el Paleolítico, incluyendo la creación de herramientas de piedra, madera y otros materiales para facilitar la vida cotidiana y satisfacer necesidades básicas. También discute cómo el desarrollo del fuego permitió iluminación, calefacción, cocción de alimentos y señalización, así como las viviendas de cuevas y cabañas construidas con ramas, barro y huesos según patrones climáticos. Explica que los grupos se organizaban en
高雄醫師會誌94期-專刊~高雄市醫師公會登山隊
The document appears to be notes containing various dates and numbers, including dates from 2008 to 2018, numbers ranging from 3 to 1000, and references to snow, peaks, and brands such as Chanel. It is difficult to determine the overall context or meaning based on the limited and disconnected information provided.
高雄醫師會誌94期-會員園地~吳玉心-走跳倫敦地標
The document appears to provide information about three tall buildings: The Shard in London, completed in 2012 and standing 310 meters tall; the Swiss Re Headquarters building in Zurich completed in 180 meters tall; and references the London Eye ferris wheel built in 1999 standing 135 meters tall. It lists various statistics about the buildings such as height, number of floors, and construction dates.
Viewers also liked (15)
Belinda Waller and Andrew Williams' presentation at Mumbrella's Retail Market...
Belinda Waller and Andrew Williams' presentation at Mumbrella's Retail Market...
Similar to 高雄醫師會誌94期-病例討論~張盛皇、王照元-癌思停(Bevacizumab)治療轉移性結直腸癌導致之偽動脈瘤破裂
MON 2011 - Slide 12 - C. Sessa - Cervical and endometrial cancers
The document discusses cervical cancer, including epidemiology, diagnosis, staging, treatment, and ongoing clinical trials. It recommends that concurrent chemoradiation with cisplatin is the standard treatment for locally advanced cervical cancer based on results from randomized trials showing improved survival compared to radiation alone. Fertility-sparing surgery may be an option for early-stage disease. Ongoing trials are investigating neoadjuvant chemotherapy and targeted agents for recurrent or metastatic cervical cancer.
MCO 2011 - Slide 15 - C. Sessa - Cervical and endometrial cancers (part II)
MCO 2011 - Slide 15 - C. Sessa - Cervical and endometrial cancers (part II)European School of Oncology
The document discusses the treatment of cervical cancer. It recommends that concurrent chemoradiation with cisplatin is the standard treatment for locally advanced cervical cancer based on evidence from randomized trials showing improved survival. Neoadjuvant chemotherapy followed by surgery may be an alternative approach currently being tested in clinical trials. Bevacizumab is being studied as a potential targeted therapy in advanced or recurrent cervical cancer.Should triple negative breast cancer (tnbc) subtype
Triple-negative breast cancer (TNBC) is an aggressive subtype without targets for hormonal or HER2-directed therapy. While some studies found higher local recurrence rates with breast conservation for TNBC, other large studies found equivalent survival compared to mastectomy. Genetic testing is recommended for TNBC patients to guide risk-reducing interventions. For a patient with early-stage TNBC treated with lumpectomy, conventional whole-breast radiotherapy with boost is recommended to reduce the risk of local recurrence due to the aggressive nature of TNBC.
Update on Management of Triple Negative Breast Cancer
This document provides an update on the management of triple negative breast cancer from Dr. Banu Arun at MD Anderson Cancer Center. It discusses that triple negative breast cancer is a heterogeneous disease comprised of several molecular subtypes with different characteristics and potential treatment targets. Clinical trials exploring chemotherapy regimens, platinum agents, PARP inhibitors, anti-angiogenic drugs, and immunotherapies are summarized. Ongoing research aims to better define the subtypes in order to personalize treatment for triple negative breast cancer patients.
Treatment Options for Cancer of the Bladder
Early stage bladder cancer is typically treated with surgery (transurethral resection) followed by chemotherapy or immunotherapy delivered directly into the bladder. Muscle-invasive bladder cancer may be treated with surgery (partial or total cystectomy), sometimes preceded or followed by chemotherapy and/or radiation. For advanced or unresectable bladder cancer, options include chemotherapy, radiation alone, or chemoradiation. Bladder preservation protocols use chemoradiation to attempt curing the cancer without surgery. Radiation is also used post-operatively or palliatively to treat symptoms.
CaCu localizado.pdf
This document summarizes a presentation on the current management of locally advanced cervical cancer. It discusses the definition of locally advanced cervical cancer per FIGO staging criteria and the importance of imaging for diagnosis, nodal staging, and assessing distant metastases. A variety of imaging modalities are used, including MRI, PET/CT, and CT, to accurately stage disease prior to and following treatment, which typically involves chemotherapy and radiation therapy. Nodal staging is especially important for prognosis and determining appropriate treatment planning.
Update on clinical trials in cervical cancer
Congreso de cáncer de cérvix, organizado por René Pareja, Lina Trujillo y Claudia Calle, Hotel Interecontinental Medellín, Junio 22-24, 2017
triple negative breast cancer
The document discusses classification and treatment of triple negative breast cancer (TNBC). It begins with an overview of TNBC classification including molecular subtypes. It then describes the clinical characteristics and prognosis of TNBC compared to other breast cancer types. Treatment options discussed include chemotherapy with taxanes and platinum agents shown to be effective. Other potential targeted therapies mentioned include PARP inhibitors, EGFR inhibitors, angiogenesis inhibitors, and tyrosine kinase inhibitors.
The Molecular Analysis on Circulating Tumor Cells to Determine Prognostic and...
Circulating tumor cells (CTCs) is an emerging source used molecular cancer diagnostics. Through expression profiling of CTCs, it allows a deeper understanding about which metabolic pathways enable tumor cells to survive in the circulation, how they become resistant to a drug regimen, how they transform and adapt and, finally, which cellular markers should targeted for future therapies.
This webinar will introduce the AdnaTest CTC detection platform which has been proven in several clinical trials to provide prognostic and predictive information in breast, ovarian and prostate cancer. The platform by itself is still open for research and allows access to any potential target of interest. Join us to learn more about this novel platform, its technology and applications in liquid biopsy.
What is role of pathologist
The role of the pathologist in clinical pathology is to oversee the laboratory testing cycle and provide guidance to clinicians. Pathologists can uniquely contribute by:
1) Guiding clinicians on appropriate test selection from the large test menu.
2) Guiding appropriate testing to avoid unnecessary tests that increase the risk of false positives.
3) Interpreting laboratory results in the proper clinical context since primary data can be uninformative without considering the clinical scenario.
breast cancer
This document provides an overview of breast cancer therapy. It discusses that breast cancer treatment is multidisciplinary, involving surgery, radiation, and systemic therapy. For early-stage breast cancer, the majority of women are candidates for either breast-conserving surgery plus radiation or mastectomy, as the risks and survival outcomes are similar between the two approaches. Adjuvant systemic therapy is used based on proven survival benefits and molecular profiling to individualize treatment.
H. Khaled - Bladder cancer - State of the art
This document summarizes the management of urinary bladder cancer. It discusses staging, histopathologic types, and treatment options for non-muscle invasive and muscle invasive bladder cancer as well as metastatic disease. Standard first-line chemotherapy for metastatic bladder cancer includes gemcitabine and cisplatin or MVAC. Newer chemotherapy regimens and agents are also discussed.
Ovarian cancer
1. Ovarian cancer is the second most common gynecologic malignancy in the US, with most cases presenting at advanced stages.
2. Recurrent disease is common, even after initial treatment, and targeting angiogenesis through VEGF inhibition has shown promising results both as single agent therapy and in combination with chemotherapy.
3. Bevacizumab has been approved as front-line treatment combined with chemotherapy based on improved progression-free survival seen in clinical trials, though no overall survival benefit has been proven.
neoadjuvant chemotherapy in TNBC and BRCA mutated BREAST CANCER
Neoadjuvant chemotherapy provides several benefits for breast cancer treatment compared to adjuvant chemotherapy. Studies have shown neoadjuvant chemotherapy can increase rates of breast conserving surgery, predict response to therapy through assessment of pathological complete response, and improve survival outcomes. For triple negative and BRCA-mutated breast cancers specifically, the addition of platinum agents or PARP inhibitors to neoadjuvant regimens may improve pathological complete response rates compared to standard anthracycline and taxane chemotherapy alone.
gopalan031607
Ovarian cancer is the 8th most common cancer in women and the 5th leading cause of cancer death. It has a median age of diagnosis of 60 years old and 68% of cases are metastatic at diagnosis. Risk factors include family history, personal history of breast cancer, infertility, and lack of pregnancy. Genetic mutations like BRCA1/2 account for 10-15% of cases. Symptoms are often vague. Treatment involves surgical staging and debulking followed by platinum-based chemotherapy, with the goal of optimal cytoreduction to ≤1cm residual disease.
Pancreatic Cancer Are We Moving Forward Yet
This summary provides an overview of key findings from studies presented at the 2007 Gastrointestinal Cancers Symposium on treatments for pancreatic cancer:
1) A phase III trial found that adding bevacizumab to gemcitabine did not improve survival for advanced pancreatic cancer.
2) A phase II study showed promising results for cetuximab plus gemcitabine/oxaliplatin, with a high response rate and tolerable toxicity.
3) Population-based analyses found adjuvant radiotherapy after surgery and chemo-radiotherapy improved survival outcomes for pancreatic cancer.
R. Gaafar - Lung cancer - Guidelines and clinical case presentation (2-3 cases)
R. Gaafar - Lung cancer - Guidelines and clinical case presentation (2-3 cases)European School of Oncology
The document provides guidelines for the treatment of advanced non-small cell lung cancer. It recommends that first-line therapy should consist of platinum-based combination chemotherapy for patients with good performance status. For patients with EGFR mutations, an EGFR tyrosine kinase inhibitor is the preferred first-line treatment. It also recommends the addition of bevacizumab or cetuximab to platinum-based chemotherapy for certain patients.J.B. Vermorken - Ovarian cancer - State of the art
This document summarizes key information about ovarian cancer, including epidemiology, staging, treatment milestones, prognostic factors, and recent clinical trials. It notes that the median age of diagnosis is 63 years and discusses improvements in 5-year survival over time. New developments discussed include the role of surgery, chemotherapy regimens, targeted therapies like bevacizumab, and trials in recurrent settings.
What 2015 Holds for Colorectal Cancer #CRCWebinar
To share the knowledge from 2015 GI ASCO, Dr. Al Benson, one of FightCRC Medical Advisory Board members, and Andi Dwyer discuss key highlights as they pertain to colorectal cancer from the symposium and what they mean for patients.
Knowledge is Power: ovarian cancer
The document discusses a clinical trial called GOG 218 that evaluated the use of the drug bevacizumab for the primary treatment of advanced epithelial ovarian cancer. The trial found that patients who received bevacizumab plus chemotherapy had a 3 month improvement in progression-free survival compared to those who received chemotherapy alone. Bevacizumab is the first molecular targeted therapy and anti-angiogenic agent to demonstrate a benefit in upfront treatment of ovarian cancer. While survival was not yet improved, the trial provides support for further research evaluating bevacizumab and other targeted agents to improve outcomes for ovarian cancer patients.
Similar to 高雄醫師會誌94期-病例討論~張盛皇、王照元-癌思停(Bevacizumab)治療轉移性結直腸癌導致之偽動脈瘤破裂 (20)
MON 2011 - Slide 12 - C. Sessa - Cervical and endometrial cancers
MON 2011 - Slide 12 - C. Sessa - Cervical and endometrial cancers
MCO 2011 - Slide 15 - C. Sessa - Cervical and endometrial cancers (part II)
MCO 2011 - Slide 15 - C. Sessa - Cervical and endometrial cancers (part II)
Should triple negative breast cancer (tnbc) subtype
Should triple negative breast cancer (tnbc) subtype
Update on Management of Triple Negative Breast Cancer
Update on Management of Triple Negative Breast Cancer
The Molecular Analysis on Circulating Tumor Cells to Determine Prognostic and...
The Molecular Analysis on Circulating Tumor Cells to Determine Prognostic and...
neoadjuvant chemotherapy in TNBC and BRCA mutated BREAST CANCER
neoadjuvant chemotherapy in TNBC and BRCA mutated BREAST CANCER
R. Gaafar - Lung cancer - Guidelines and clinical case presentation (2-3 cases)
R. Gaafar - Lung cancer - Guidelines and clinical case presentation (2-3 cases)
J.B. Vermorken - Ovarian cancer - State of the art
J.B. Vermorken - Ovarian cancer - State of the art
Recently uploaded
Cell Therapy Expansion and Challenges in Autoimmune Disease
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
In some case, your chronic prostatitis may be related to over-masturbation. Generally, natural medicine Diuretic and Anti-inflammatory Pill can help mee get a cure.
Journal Article Review on Rasamanikya
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Explore the benefits of combining Ayurveda with conventional Parkinson's treatments. Learn how a holistic approach can manage symptoms, enhance well-being, and balance body energies. Discover the steps to safely integrate Ayurvedic practices into your Parkinson’s care plan, including expert guidance on diet, herbal remedies, and lifestyle modifications.
Dehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in Dehradun
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by Stamler, Verified Chapters 1 - 33, Complete Newest Version Community Health Nursing A Canadian Perspective, 5th Edition by Stamler, Verified Chapters 1 - 33, Complete Newest Version Community Health Nursing A Canadian Perspective, 5th Edition by Stamler Community Health Nursing A Canadian Perspective, 5th Edition TEST BANK by Stamler Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Pdf Chapters Download Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Pdf Download Stuvia Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Study Guide Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Ebook Download Stuvia Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Questions and Answers Quizlet Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Studocu Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Quizlet Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Pdf Chapters Download Community Health Nursing A Canadian Perspective, 5th Edition Pdf Download Course Hero Community Health Nursing A Canadian Perspective, 5th Edition Answers Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Ebook Download Course hero Community Health Nursing A Canadian Perspective, 5th Edition Questions and Answers Community Health Nursing A Canadian Perspective, 5th Edition Studocu Community Health Nursing A Canadian Perspective, 5th Edition Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Pdf Chapters Download Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Pdf Download Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Study Guide Questions and Answers Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Ebook Download Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Questions Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Studocu Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Stuvia
Top-Vitamin-Supplement-Brands-in-India List
Swisschem Dermacare provides the Top 10 Vitamin Supplement Brands in India. To know more about us give us call at our official number
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidadeProf. Marcus Renato de Carvalho
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Top Effective Soaps for Fungal Skin Infections in India
Swisschem Dermacare has mentioned the List of The Best Antifungal Soap In India 2022. All of these soaps are trusted by various Dermatology Experts.
share - Lions, tigers, AI and health misinformation, oh my!.pptx
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
ABDOMINAL TRAUMA in pediatrics part one.
Abdominal trauma in pediatrics refers to injuries or damage to the abdominal organs in children. It can occur due to various causes such as falls, motor vehicle accidents, sports-related injuries, and physical abuse. Children are more vulnerable to abdominal trauma due to their unique anatomical and physiological characteristics. Signs and symptoms include abdominal pain, tenderness, distension, vomiting, and signs of shock. Diagnosis involves physical examination, imaging studies, and laboratory tests. Management depends on the severity and may involve conservative treatment or surgical intervention. Prevention is crucial in reducing the incidence of abdominal trauma in children.
Efficacy of Avartana Sneha in Ayurveda
Avartana Sneha is a unique method of Preparation of Sneha Kalpana in Ayurveda, mainly it is indicated for the Vataja rogas.
Role of Mukta Pishti in the Management of Hyperthyroidism
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
Recently uploaded (20)
Cell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune Disease
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Dehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in Dehradun
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Top Effective Soaps for Fungal Skin Infections in India
Top Effective Soaps for Fungal Skin Infections in India
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
Role of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of Hyperthyroidism
高雄醫師會誌94期-病例討論~張盛皇、王照元-癌思停(Bevacizumab)治療轉移性結直腸癌導致之偽動脈瘤破裂
- 1. 簡介: Bevacizumab( Avast- in ) Bevacizumab 0.03% (Bevacizumab) 病例報告: 65 (cT4aN2aM1b, Stage: IVB) 2016/04/29 (FOLFIRI) 2016/5/13 (Bevacizumab) FOLFIRI (Bevacizumab)
- 2. ( ) ( ) 討論: (Bevacizumab) 42902 11 0.03% 6 12 (Bevacizumab) ( ) Cartwright T, Hainsworth J, Heim W, Berlin J, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Patel T, Hamm JT, Hecht JR, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial. patients treated with bevacizumab combination
- 3. Bevacizumab in the management S, Kretzschmar A, Michael M, Dibartolomeo M, et al. Safety and efficacy of first line bevacizumab and fluoropyrimidines in metastatic patients with cancer treated with bevacizumab: a meta-analysis of